Registry updateRetina
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Completed. Phase 2. Registered enrolment: 300. Aviceda Therapeutics, Inc.
Phase 2
Trial registryNCT05839041
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Trial at a glance
- NCT
- NCT05839041
- Sponsor
- Aviceda Therapeutics, Inc.
- Phase
- Phase 2
- Indication
- Geographic Atrophy of the Macula; Macular Degeneration
- Registered enrollment
- 300
- Recruitment
- Completed
- Primary completion
- 2026-02-18
- Last registry update
- 2026-09-16
- Results posted
- No
What changed
This is the available registry snapshot. An earlier comparable revision is not available.
Clinical trials
Registry updateRetina
Geographic atrophy: the SIGLEC record is updated
ClinicalTrials.gov lists the phase II AVD-104 study as completed. The registry record was updated on 16 September; no results are posted in the retrieved record.
Trial registry